Comparison Of Conjunctival Autograft And Topical Mitomycin C In Primary Pterygium Surgery For Prevention Of Recurrence: A Tertiary Care Centre

Authors

  • Paridhi
  • Rubie Malhotra
  • Mohd. Mobin
  • Khalida Sayeed

Keywords:

Pterygium, Conjunctival Limbal Autograft (CLAG), Mitomycin C (MMC), Recurrence, Visual Acuity, Tear Film, Randomized Controlled Trial, Ocular Surface, Pterygium Surgery, Postoperative Complications

Abstract

Background: Pterygium is a common ocular surface disorder characterized by a fibrovascular growth of conjunctival tissue onto the cornea. Surgical excision is the primary treatment, but recurrence remains a significant challenge. This study compares the efficacy and safety of conjunctival limbal autograft (CLAG) and intraoperative topical Mitomycin C (MMC) in preventing recurrence after primary pterygium surgery.

Methods: A hospital-based randomized controlled trial was conducted at the Department of Ophthalmology, IIMS&R, Lucknow, involving 70 patients with primary pterygium. Participants were randomly assigned to Group A (MMC, n=35) or Group B (CLAG, n=35). Preoperative and postoperative assessments included visual acuity, tear film tests (TBUT and Schirmer's), slit lamp examination, and recurrence grading using Prabhasawat's classification. Patients were followed for 6 months.

Results: Recurrence was observed in 8.5% of Group A and 2.8% of Group B at 6 months. The mean time to recurrence was slightly earlier in the MMC group (175.14 ± 5.26 days) compared to the CLAG group (178.43 ± 2.12 days). Postoperative complications like corneal haze were more common in the MMC group. Visual acuity improved in both groups, but CLAG had better postoperative stability and fewer complications.

Conclusion: Both CLAG and MMC are effective in reducing pterygium recurrence, but CLAG is superior in terms of lower recurrence and complication rates. It is recommended as the preferred surgical approach in primary pterygium cases.

Downloads

Download data is not yet available.

References

Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007;18(4):308–313.

Kenyon KR, Wagoner MD, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 1985;92(11):1461–1470.

Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997;104(6):974–985.

Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an alteration of normal limbal epithelial stem cells. Invest Ophthalmol Vis Sci. 1994;35(9):3210–3224.

Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin C after pterygium surgery. Ophthalmology. 1992;99(11):1647–1654.

Frucht-Pery J, Ilsar M. The use of low-dose mitomycin C for prevention of recurrent pterygium. Am J Ophthalmol. 1994;118(6):789–792.

Rao SK, Lekha T, Sitalakshmi G, Padmanabhan P. Conjunctival-limbal autografts for pterygia and the problem of conjunctival melanosis. Cornea. 2004;23(5):524–529.

Young AL, Leung GY, Wong AK, Cheng LL, Lam DS. A randomized trial comparing 0.02% mitomycin C and limbal conjunctival autograft in the treatment of primary pterygium. Am J Ophthalmol. 2004;138(6):1041–1048.

Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on recurrence after excision. Arch Ophthalmol. 1997;115(10):1235–1240.

Mandal PC, Das A, Padhy SK. Role of age in pterygium recurrence. Int J Ophthalmol. 2014;7(3):600–604.

Downloads

Published

2025-07-03

How to Cite

1.
Paridhi P, Malhotra R, Mobin M, Sayeed K. Comparison Of Conjunctival Autograft And Topical Mitomycin C In Primary Pterygium Surgery For Prevention Of Recurrence: A Tertiary Care Centre. J Neonatal Surg [Internet]. 2025Jul.3 [cited 2025Jul.19];14(32S):3477-85. Available from: https://jneonatalsurg.com/index.php/jns/article/view/7951

Issue

Vol. 14 No. 32S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.